March 3 (Reuters) - Theravance Biopharma Inc TBPH.O:
THERAVANCE BIOPHARMA REPORTS PHASE 3 CYPRESS STUDY DID NOT MEET PRIMARY ENDPOINT; BOARD ACCELERATES STRATEGIC REVIEW AND ANNOUNCES COST REDUCTION ACTIONS
THERAVANCE BIOPHARMA REPORTS PHASE 3 CYPRESS STUDY DID NOT MEET PRIMARY ENDPOINT; BOARD ACCELERATES STRATEGIC REVIEW AND ANNOUNCES COST REDUCTION ACTIONS
THERAVANCE BIOPHARMA INC: PHASE 3 CYPRESS STUDY DID NOT MEET PRIMARY ENDPOINT
THERAVANCE BIOPHARMA INC: STRATEGIC REVIEW COMMITTEE ACCELERATING ONGOING EFFORTS TO EVALUATE ALTERNATIVES TO MAXIMIZE SHAREHOLDER VALUE
THERAVANCE BIOPHARMA INC: ORGANIZATIONAL RESTRUCTURING TO REDUCE COST BASE BY APPROXIMATELY 60%
THERAVANCE BIOPHARMA INC: ORGANIZATIONAL RESTRUCTURING TO REDUCE COST BASE BY APPROXIMATELY 60% (OR APPROXIMATELY $70 MILLION)
THERAVANCE BIOPHARMA INC: RESTRUCTURING EXPECTED TO RESULT IN COMPANY GENERATING APPROXIMATELY $60 - $70 MILLION OF ANNUALIZED CASH FLOW
THERAVANCE BIOPHARMA INC: RESTRUCTURING EXPECTED TO RESULT IN COMPANY GENERATING APPROXIMATELY $60 - $70 MILLION OF ANNUALIZED CASH FLOW
THERAVANCE BIOPHARMA INC: RESTRUCTURING IS EXPECTED TO IMPACT APPROXIMATELY 50% OF OVERALL WORKFORCE
THERAVANCE BIOPHARMA INC: REDUCTION INCLUDES COMPLETE WIND-DOWN OF RESEARCH AND DEVELOPMENT ORGANIZATION AND A DECREASE OF APPROXIMATELY 50% IN G&A EMPLOYEES
THERAVANCE BIOPHARMA INC: EXPECTS TO INCUR APPROXIMATELY $5 TO $7 MILLION IN ONE-TIME CASH SEVERANCE COSTS
Source text: ID:nPn5Znz84a
Further company coverage: TBPH.O
((Reuters.Briefs@thomsonreuters.com;))